polski | english | login
Array|Array|Array|Array|Array|Array

DOI: 10.18544/PEDM-22.02.0052
Pediatr Endocrinol Diabetes Metab 2016;22,2:60-65

Impact of SIRT1 gene expression on the development and treatment of the metabolic syndrome in oncological patients

Joanna Wawryka, Ewa Barg

Key words

sirtuin 1,metabolic syndrome, acute lymphoblastic leukemia, SIRT1 gene, diabetes mellitus type 2, obesity

Abstract

Sirtuins – products of gene SIRT expression have been divided into 7 classes, according to the amino acid composition and location of the cell. Those factors, called longevities proteins, are a group of histone deacetylases, depend on nicotinamide adenine dinucleotide (NAD). Particularly noteworthy is the protein sirtuin 1, which further deacetylates numerous transcription factors, receptors and enzymes. Through its action reduces the activity of glucocorticoid receptors in the body. Products of gene SIRT1 expression is responsible for apoptosis, differentiation, senescence cells, also affect the regulation of carbohydrate and lipid metabolism. Cardioprotective and hypotensive impact is also very important. SIRT1 reduces the accumulation of fat and decreases the risk of visceral obesity. Low gene expression of SIRT1 therefore predispose to the development of metabolic syndrome. Homeostasis sirtuin 1 disorders can also be observed in certain neoplastic diseases, primarily hormone-dependent breast, ovarian and prostate cancer, as well as it can cause leukemias and lymphomas. Components, activating expression of gen SIRT1 or a molecule with biological properties sirtuin 1, may have promising impact for treatment of diabetes mellitus type 2, obesity, hypertension, dyslipidemia. Analyzing, the pleiotropic effect of sirtuin 1 and numerous metabolic pathways, appear to be particularly beneficial effect of supplementation molecules increasing the level of expression gene SIRT1, in treatment of acute lymphoblastic leukemia with using high-dosing glicocorticosteroid therapy. Which would reduce the number of early and late complications of oncological treatment and increase patient survival. Compound requires further study.


Article published in polish language



advanced search »

Article in databases

DOI: 10.18544/PEDM-22.02.0052
PUBMED: view

Similar articles

Growth hormone therapy in a girl with Turner syndrome and diabetes type ...

...

Sugar content in non-alcoholic beverages and dietary recemmendations for ...

The impact of having siblings – analysis of “hygiene theory” of chronic ...

Risk factors for cardiovascular disease in children with type 1 diabetes ...

Pediatric Endocrinology Diabetes and Metabolism

2018; 24, 1: 1-51
2017; 23, 4: 169-222
2017; 23, 3: 117-168
2017; 23, 2: 59-116
2017; 23, 1: 1-58
2016; 22, 4: 133-180
2016; 22, 3: 81-132
2016; 22, 2: 43-79
2016; 22, 1: 1-42
2015; 21, 4: 149-191
2015; 21, 3: 97-148
2015; 21, 2: 51-96
2015; 21, 1: 1-50
2014; 20, 4: 131-182
2014; 20, 3: 83-130
2014; 20, 2: 35-82